Drug Profile
Research programme: diabetes therapeutics - NGM Biopharmaceuticals/Daiichi Sankyo
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company; NGM Biopharmaceuticals
- Developer Daiichi Sankyo Company
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Diabetes-mellitus in USA
- 28 Mar 2012 Early research in Diabetes mellitus in USA (unspecified route)